文献速递精神分裂症与精神病性障碍心境障碍

精神分裂症共病重性抑郁障碍的缓解情况:FACE-SZ队列结果

Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort.
PubMed 文献 · Br J Psychiatry · 2018-06-06

该研究纳入613例精神分裂症患者,28.5%存在当前重性抑郁障碍(MDD)。抗抑郁药治疗与更低的抑郁症状评分相关(5.4 vs 9.5,P<0.0001),但44.1%接受治疗的患者仍未缓解。未缓解与更多偏执妄想和当前酒精滥用障碍相关,MDD与代谢综合征相关。

要点

  • 精神分裂症患者中MDD患病率为28.5%,抗抑郁药治疗者抑郁评分更低但44.1%未缓解。
  • 未缓解MDD与偏执妄想(OR 2.3,P=0.009)和酒精滥用障碍(OR 4.8,P=0.04)相关。
  • MDD与代谢综合征相关(31.4% vs 20.2%,P=0.006),但与C反应蛋白升高无关。

核心结论

  • 抗抑郁药给药与精神分裂症共病MDD患者更低的抑郁症状水平相关,但44.1%治疗者仍未缓解。
  • 治疗未缓解时应特别探查和处理偏执妄想与酒精滥用障碍。
  • 代谢综合征可能在精神分裂症患者MDD的发生和/或维持中起作用。

研究设计与样本

  • 研究纳入FondaMental精神分裂症专家中心的613例患者,接受全面临床评估。
  • MDD定义为Calgary评分≥6分;未缓解MDD定义为当前抗抑郁药治疗(剂量不变>8周)且当前Calgary评分≥6分。

主要发现

  • 613例中175例(28.5%)被识别为当前MDD。
  • MDD显著与偏执妄想(OR 1.8;P=0.01)、意志缺乏(OR 1.8;P=0.02)、情感平淡(OR 1.7;P=0.04)和苯二氮䓬类药物使用(OR 1.8;P=0.02)相关。
  • 抗抑郁药与更低的抑郁症状评分相关(5.4 vs 9.5;P<0.0001),但44.1%治疗患者仍为未缓解MDD。
  • 未缓解者偏执妄想更多(OR 2.3;P=0.009),当前酒精滥用障碍更多(OR 4.8;P=0.04)。
  • 未发现哪种抗抑郁药类别或特定抗精神病药与更高或更低的抗抑郁治疗反应相关。

关键数值与推荐

  • MDD诊断标准:Calgary评分≥6分。
  • 未缓解MDD标准:当前抗抑郁药治疗(剂量不变>8周)且当前Calgary评分≥6分。
  • 抗抑郁药治疗者抑郁症状评分5.4 vs 未治疗者9.5(P<0.0001)。
  • MDD与代谢综合征相关:31.4% vs 20.2%(P=0.006)。

临床怎么用

  • 对精神分裂症共病MDD患者应评估并治疗偏执妄想和酒精滥用障碍,尤其治疗未缓解时。
  • 抗抑郁药治疗可降低抑郁症状水平,但需监测未缓解情况并处理相关因素。
  • 应关注精神分裂症患者的代谢综合征,其可能与MDD发生和/或维持相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Major depressive disorder (MDD) is underdiagnosed and undertreated in schizophrenia, and has been strongly associated with impaired quality of life.AimsTo determine the prevalence and associated factors of MDD and unremitted MDD in schizophrenia, to compare treated and non-treated MDD. METHOD: Participants were included in the FondaMental Expert Centers for Schizophrenia and received a thorough clinical assessment. MDD was defined by a Calgary score ≥6. Non-remitted MDD was defined by current antidepressant treatment (unchanged for >8 weeks) and current Calgary score ≥6. RESULTS: 613 patients were included and 175 (28.5%) were identified with current MDD. MDD has been significantly associated with respectively paranoid delusion (odds ratio 1.8; P = 0.01), avolition (odds ratio 1.8; P = 0.02), blunted affect (odds ratio 1.7; P = 0.04) and benzodiazepine consumption (odds ratio 1.8; P = 0.02). Antidepressants were associated with lower depressive symptoms score (5.4 v. 9.5; P < 0.0001); however, 44.1% of treated patients remained in non-remittance MDD. Nonremitters were found to have more paranoid delusion (odds ratio 2.3; P = 0.009) and more current alcohol misuse disorder (odds ratio 4.8; P = 0.04). No antidepressant class or specific antipsychotic were associated with higher or lower response to antidepressant treatment. MDD was associated with Metabolic syndrome (31.4 v. 20.2%; P = 0.006) but not with increased C-reactive protein. CONCLUSIONS: Antidepressant administration is associated with lower depressive symptom level in patients with schizophrenia and MDD. Paranoid delusions and alcohol misuse disorder should be specifically explored and treated in cases of non-remission under treatment. MetS may play a role in MDD onset and/or maintenance in patients with schizophrenia.Declaration of interestNone.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Fond G, Boyer L, Berna F, et al. Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort. Br J Psychiatry. 2018. PMID: 29871707. doi:10.1192/bjp.2018.87

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。